Alpha Cure Therapeutics develops precision safe radioligand therapy for cancer treatment, including TNBC. Their approach uses a single small molecule with a two-punch mechanism to target specific genetic mutations in cancer cells. This non-radioactive medicine aims to lethally kill cancer while minimizing damage to healthy tissues, enhancing both efficacy and safety.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with mutation-driven cancers such as triple‑negative breast cancer often lack targeted systemic therapies that can eradicate tumor cells without harming surrounding healthy tissue. Existing radioligand treatments rely on radioactive isotopes, which pose safety concerns and limit dosing flexibility. Consequently, clinicians face trade‑offs between efficacy and toxicity.
Solution
Alpha Cure Therapeutics delivers a precision‑SAFE radioligand therapy built around a single, non‑radioactive small‑molecule ligand. The molecule employs a two‑punch mechanism: high‑affinity binding to cancer‑specific genetic mutations followed by localized delivery of a cytotoxic payload. By restricting activity to mutant cells, the approach maximizes tumor kill while sparing normal tissue, improving the therapeutic index. Treatment can be completed in one or two administrations, reducing patient burden and healthcare resource use. The platform is adaptable to multiple oncogenic mutations, enabling personalized regimens across diverse tumor types.
Target Audience
The primary customers are oncology physicians and precision‑medicine programs treating mutation‑driven cancers, especially triple‑negative breast cancer, as well as academic cancer centers developing genotype‑guided therapeutic protocols.
Features
- Single small‑molecule radioligand engineered for mutation‑specific binding (e.g., BRCA1/2, TP53)
- Two‑punch mechanism: selective receptor engagement plus on‑target cytotoxic release
- Non‑radioactive payload eliminates ionizing radiation exposure and associated safety constraints
- Pharmacokinetic profile optimized for rapid tumor uptake and swift clearance from healthy organs
- Compatibility with companion diagnostic assays to identify eligible patients based on genomic profiling
- Administration protocol designed for one‑ to two‑dose regimens, simplifying outpatient delivery
- Scalable synthesis process supporting GMP manufacturing and broad clinical deployment